Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults

AIDS

Volumn 29, Issue 6, 2015, Pages 739-743

  Rainone, Veronica ^a   Giacomet, Vania ^a   Penagini, Francesca ^b   Fabiano, Valentina ^b   Calascibetta, Francesca ^a   Mameli, Chiara ^b   Pisanelli, Stefania ^a   Zuccotti, Gian Vincenzo ^b   Clerici, Mario ^b,c   Trabattoni, Daria ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; WART VIRUS VACCINE; CYTOKINE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CELLULAR SECRETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; LYMPHOCYTE SUBPOPULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS IMMUNITY; ADOLESCENT; COMPLICATION; DRUG EFFECTS; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; LONGITUDINAL STUDY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; PROSPECTIVE STUDY; SECRETION (PROCESS); T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

ADOLESCENT; CYTOKINES; HIV INFECTIONS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNITY, CELLULAR; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; VACCINATION; YOUNG ADULT;

EID: 84937916535     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000597     Document Type: Article

References (20)

1. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS 2009; 4:52-56.
2. Palefsky J. Cervical human papillomavirus infection and cervicalintraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 2003; 15:382-388.
3. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T, Crowley-Nowick PA, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000; 154:127-134.
4. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500-1510.
5. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-1466.
6. Giacomet V, Penagini F, Trabattoni D, Viganò A, Rainone V, Bernazzani G, et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 2014; 32:5657-5661.
7. Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M, et al. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS 2013; 27:381-389.
8. Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118:3263-3272.
9. Centers for Disease Control and Prevention (CDC). Recommendations on the use of the quadrivalent human papillomavirus in males - Advisory Committee on Immunization Practices-United States, 2013. MMWR Morb Mortal Wkly Rep 2011; 60:1705-1708.
10. Levin MJ, Moscicki AB, Song LY, Fenton T, MeyerWA3rd, Read JS, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIVinfected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197-204.
11. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246-1253.
12. Meyer SI, Fuglsang K, Blaakaer J. Cell-mediated immune response: a clinical review of the therapeutic potential of HPV vaccination. Acta Obstet Gynecol Scand 2014; 93:1209-1218.
13. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 2001; 401:708-712.
14. Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J Infect 2014; 69:533-545.
15. Adler DH. The impact of HAART on HPV-related cervical disease. Curr HIV Res 2010; 8:493-497.
16. Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 2010; 10:499-503.
17. Viganoi A, Principi N, Villa ML, Riva C, Crupi L, Trabattoni D, et al. Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. J Pediatr 1995; 126:368-374.
18. Viganò A, Balotta C, Trabattoni D, Salvaggio A, Riva C, Bricalli D, et al. Virologic and immunologic markers of disease progression in pediatric HIV infection. AIDS Res Hum Retroviruses 1996; 12:1255-1262.
19. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
20. Palefsky J. Human papillomavirus-related tumors in HIV. Curr Opin Oncol 2006; 18:463-468.